



Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

A European off-patent industry for access, availability, and affordability

### Wednesday 29 June 2022

15.30 16.30



**REGISTRATION AND WELCOME COFFEE** 

16.30 16.35



**IP SESSION - OPENING ADDRESSES** 

**Adrian van den Hoven** – Director General, Medicines for Europe **Stella Kyriakides** – Commissioner, Health and Food Safety, European Commission

16.3518.00



OPTIONAL\* INTELLECTUAL PROPERTY SESSION

The future of the industry: from an IP to a holistic approach

**Moderator: Adrian van den Hoven** – Director General, Medicines for Europe **Panellists:** 

- Paul Csiszár Director, DG Competition, European Commission
- Agnieszka Deeg-Tyburska General Counsel, Polpharma Group
- Ingrid Sollerer General Counsel & Global Head Legal, Sandoz
- Ana Marti General Counsel & IP, Medichem
- Tomos Shillingford General Counsel, Insud Pharma
- Bibianne Bon General Counsel Europe, Teva

Questions & answers

\*For Annual Conference Participants, registration for this session must be confirmed during the conference registration process or by sending a separate email to events@medicinesforeurope.com before 17 June 2022

19.30 21.30



CONFERENCE REGISTRATION AND WELCOME COCKTAIL AT THE CONFERENCE HOTEL





Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

### Thursday 30 June 2022

08.00 09.00



**WELCOME COFFEE** 

09.00 09.45



#### **WELCOME ADDRESS**

Elisabeth Stampa – President, Medicines for Europe and CEO, Medichem

Margaritis Schinas – Vice President, Promoting our European way of Life, European Commission

09.45 11.15



#### **SESSION 1 – Future-proofing healthcare systems in Europe**

The consequences of the COVID-19 pandemic are far-reaching and impacting healthcare systems globally. The opening session will present an overview of the status of health systems, as well as provide the state of play of the off-patent market. During the discussion, we will look at the main challenges that healthcare systems have to overcome and how off-patent medicines can provide in a post-pandemic future.

Moderator: Suzette Kox – Secretary General, IGBA Speakers

- Rebecca Guntern Vice President of Medicines for Europe, Head of Europe Sandoz
- Per Troein Vice President Strategic Partners, IQVIA
- Dirk Van den Steen Deputy Head of Unit, Performance of national health systems,
   DG SANTE, European Commission
- Victoria Romero Pazos Patient Representative, Tripleaxel

11.15 11.45



#### **NETWORKING COFFEE BREAK**

11.4513.00



### SESSION 2 – A sustainable EU ecosystem for Value Added innovation

The Pharmaceutical strategy for Europe presents a historic opportunity for R&D investment in off-patent medicines to address unmet health needs. The industry is transforming to continuously bring value to patients through sustained innovation in off-patent medicines. In this session, we will look towards a sustainable European ecosystem to incentivise the development of value added medicines.

**Moderator: Maja Sercic** – Associate Director Policy & Market Access, Medicines for Europe **Speakers** 

- **Cristina Montané** Patient Representative at the Catalan Health System Committee for Medical Products for Human Use, Foro Español de Pacientes (FEP)
- James Burt Chief Executive Officer, Pharmanovia
- Florian Schmidt Deputy Head of Unit, Medicines: policy, authorisation and monitoring, DG SANTE, European Commission
- César Hernández García Head of Department, Department of Medicines for Human Use,





Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

13.00 14.10



**NETWORKING BUFFET LUNCH** 

14.10 14.30



#### **KEYNOTE SPEECH**

Frances Zipp – President and CEO, Lachman Consultant Services Adele Paterson – Chief Executive Office, International Health Partners Tom Roane – Vice President, Corporate Engagement & Strategy, Direct Relief

14.30 16.00



SESSION 3 – Reshaping national market policies to ensure availability

The good functioning of European markets is essential in ensuring medicines availability for patients. During this session, we will discuss new pricing and reimbursement models for generic medicines, as well as procurement reforms necessary for a more sustainable medicines market. Securing long-term competitive markets is central to supply security and to prevent medicines shortages, allowing patients to continue to have access to a broad range of therapeutic options.

Moderator: Victor Mendonça – Head of Corporate Affairs Europe, Viatris & Chair of the Generic Market **Access Committee** 

#### **Speakers**

- Thyra de Jongh Principal Consultant, Technopolis Group
- Clément François Executive Vice President HEOR, Creativ Ceutical
- Gergely Németh Project Manager, National Institute of Health Insurance Fund
- Cláudia Furtado Head of Information and Strategic Planning Office, Infarmed
- Valérie Fontaine Executive Vice President, Fresenius Kabi & Member of the Medicines for Europe Executive Committee

16.00 16.30



**NETWORKING COFFEE BREAK** 





Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

16.30 18.00



SESSION 4 – Building strong European co-operation to prevent and mitigate shortages

Concerted action at European level to address medicine shortages is more important than ever. During this session, we will discuss what role the European Union can play in preventing and mitigating medicine shortages, the latest developments with the Health Union Package and the mechanisms currently in place

Moderator: Aidan Fry – Director External Communications, STADA Group Key opening speech: Nicolás González Casares – Member of the European Parliament (S&D, Spain) **Speakers** 

- Monica Dias Head of the Supply and Availability of Medicines and Devices, European Medicines Agency (EMA)
- Domenico Di Giorgio Head of Inspection and Certification Department, Italian Medicines Agency (AIFA)
- Ancel·la Santos Senior Health Policy Officer, The European Consumer Organisation (BEUC)
- Philippe Drechsle Vice President EU Portfolio, Teva & Member of the Medicines for Europe **Executive Committee**
- Nicolás González Casares Member of the European Parliament, (S&D, Spain)

18.00 18.10



**CLOSING OF THE DAY** Jordi Valls - Vice President, AFAQUIM

19.00 23.00



**CONFERENCE DINNER** 

### Friday 1 July 2022

08.00 09.00



**WELCOME COFFEE** 


09.00 09.30



**KEYNOTE SPEECH** 

Mar Fábregas – President AESEG

Patricia Lacruz – Director General for Pharmaceuticals, Ministry of Health, Spain





Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

09.30 10.45



SESSION 5 — Incentivising a robust and global industry for resilient supply in Europe

The resilient supply of medicines is essential for European patients. The off-patent pharmaceutical industry operates in a globalised environment. During this session, we will focus on the key challenges and barriers that need to be addressed to ensure the EU remains a leader and an innovator in medicines manufacturing.

**Moderator: Michele Uda –** Director General, Egualia & Member of the Medicines for Europe Executive Committee

#### **Keynote opening speeches:**

**Pierre Delsaux** – Director-General, European Health Emergency Preparedness and Response Authority (DG HERA), European Commission

**Dolors Montserrat** – Member of the European Parliament, (EPP, ES)

#### **Panellists**

- **Pierre Delsaux** Director-General, European Health Emergency Preparedness and Response Authority (DG HERA), European Commission
- Dolors Montserrat Member of the European Parliament, (EPP, ES)
- Giacomo Mattinò Head of Unit for Agro-Food, Retail and Health ecosystems, EC DG GROW
- Galo Gutiérrez Monzoní Director General, Industry and SMEs, Ministry of Industry, Trade and Tourism, Spain
- Christian Pawlu Head of Corporate Development, Fresenius Kabi
- **Paul Tredwell** Executive Vice President, Accord Healthcare & Member of the Medicines for Europe Executive Committee

10.45 11.15



**NETWORKING COFFEE BREAK** 

11.15 12.45



SESSION 6 - Planning for the long-term: the biosimilar market in 2035

The Biosimilar medicines market is evolving. During this final panel, we will discuss national strategies and practices influencing the sustainability of the Biosimilar medicines market and patient access to biological medicines.

**Moderator: Adrian van den Hoven** – Director General, Medicines for Europe **Speakers** 

- Heikki Bothas Executive Director, Finnish Generic Pharmaceutical Association
- Isabel del Rio Deputy Director, BioSim, Spain
- Joris Van Assche Managing Director, Medaxes (Belgium) & Member of the Medicines for Europe Executive Committee
- Yannis Natsis Director, European Social Insurance Platform (ESIP)





Dolce Sitges Hotel, Sitges (Barcelona)

29 JUNE - 1 JULY 2022 - #ACCESSFORALL

12.45 13.00



**CLOSING SPEECH** 

Adrian van den Hoven – Director General, Medicines for Europe

13.00 14.30



**END OF CONFERENCE LUNCH** 

## **GOLD SPONSORS**







### **CONFERENCE SPONSORS**















### **SUPPORTING & MEDIA PARTNERS**











Follow the event on twitter #ACCESSFORALL For further information www.medicinesforeurope.com/events/annual2022